Top Markets
Coin of the day
Vincerx Pharma, Inc. Vincerx Pharma, Inc.

Vincerx Pharma, Inc.

VINC
Clasificación en acciones #40876
Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical... Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering and advancing innovative treatments for cancer, specifically addressing areas of high medical need within the U.S. Its primary therapeutic asset is VIP152, an inhibitor targeting cyclin-dependent kinase-9 (CDK9), designed for individuals battling advanced forms of cancer. Beyond this lead candidate, the company's pipeline features several preclinical-stage projects: VIP217, an orally administered PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate aimed at solid tumor treatment; and VIP943 and VIP924, both geared towards treating blood cancers. Established in 2019, Vincerx Pharma is based in Palo Alto, California.
Precio por acción
$0.0127
Última sincronización: 2026-08-12
Capitalización bursátil
$66.48K
Cambio (1 día)
-2.31%
Cambio (1 año)
-67.44%
País
US
Comercio Vincerx Pharma, Inc. (VINC)

Categoría

Ratio P/B de Vincerx Pharma, Inc. (VINC)
Ratio P/B al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Vincerx Pharma, Inc., el ratio P/B actual (TTM) es 0. Al final de 2026, el ratio P/B era 0.
Historial del ratio P/B de Vincerx Pharma, Inc. desde 2026 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
Not enough data for the provided dates.
Ratio P/B de empresas similares o competidoras
Empresa Ratio P/B Diferencia del ratio P/B País
6.2613 -
US
6.3483 -
NL
- -
CH
- -
KR
3.634 -
BE